Format

Send to

Choose Destination
See comment in PubMed Commons below
Oncologist. 2012;17(4):513-24. doi: 10.1634/theoncologist.2012-0003. Epub 2012 Apr 3.

Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.

Author information

1
Duke University Medical Center, DUMC 2823, Durham, North Carolina 27710, USA. john.strickler@dm.duke.edu

Abstract

Since its approval for the first-line treatment of metastatic colorectal cancer (mCRC), bevacizumab has become a standard treatment option in combination with chemotherapy for patients with mCRC. Bevacizumab has demonstrated efficacy in combination with a number of different backbone chemotherapy regimens, and its widespread use has introduced several important questions regarding the selection and optimization of bevacizumab-based treatment regimens, its use in various patient populations, and the identification of associated adverse events. This review discusses the results of several phase II and phase III clinical trials, as well as large observational studies, to address the use of bevacizumab in the treatment of patients with mCRC in the first-line setting.

PMID:
22477726
PMCID:
PMC3336830
DOI:
10.1634/theoncologist.2012-0003
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center